Abstract: A method for treating obstructive sleep apnea (OSA) and/or snoring that includes the step of administering to a tissue of a mammal an amount of deoxycholic acid. The method includes injecting the deoxycholic acid into a fatty tissue located in the throat, nasal cavity or mouth of the patient so as to reduce a volume of the fatty tissue.
Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a renally impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a renally impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic kidney disease with a GKA.
Type:
Grant
Filed:
June 3, 2021
Date of Patent:
January 2, 2024
Assignee:
HUA Medicine (Shanghai) Ltd.
Inventors:
Li Chen, Shuang Ren, Chengfeng Jiao, Yaohui Wang
Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.
Type:
Grant
Filed:
February 8, 2021
Date of Patent:
January 2, 2024
Assignee:
BeyondSpring Pharmaceuticals, Inc.
Inventors:
Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
Type:
Grant
Filed:
February 8, 2021
Date of Patent:
December 26, 2023
Assignee:
Romark Laboratories L.C.
Inventors:
Jean-Francois Rossignol, J. Edward Semple
Abstract: The present invention is directed to an ingestible athletic performance enhancement composition comprising l-menthol wherein the composition does not contain alcohol. The present invention further includes athletic performance enhancement compositions wherein the amount of l-menthol is between 0.01 to 0.5 weight percent of the composition. The invention also includes methods of improving athletic performance comprising the ingestion of a composition comprising l-menthol, wherein the amount of l-menthol is sufficient to induce a cooling sensation while maintaining palatability and minimizing side effects.
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type:
Grant
Filed:
April 14, 2021
Date of Patent:
December 19, 2023
Assignee:
Infirst Healthcare Limited
Inventors:
Robin M. Bannister, John Brew, Richard R. Reiley, Wilson Caparros Wanderley
Abstract: Disclosed are methods of treating Acute Respiratory Distress Syndrome using colchicine, e.g., by administering colchicine to a subject in need thereof.
Abstract: The present invention is directed to use of cannabidiol and compositions thereof as an anti-bacterial agent against multi-drug resistant bacteria such as Pseudomonas aeruginosa.
Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.
Type:
Grant
Filed:
February 18, 2021
Date of Patent:
December 5, 2023
Assignee:
VTV THERAPEUTICS LLC
Inventors:
Jennifer L. R. Freeman, Maria Carmen Valcarce Lopez
Abstract: A method of inducing HEXIM1 expression in cells of a subject includes administering to the cells a compound having the formula, and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
March 30, 2021
Date of Patent:
December 5, 2023
Assignees:
CASE WESTERN RESERVE UNIVERSITY, CLEVELAND STATE UNIVERSITY
Abstract: Methods of treating infections caused by viruses such as influenza and coronaviruses are disclosed. The methods generally include systemic administration of an effective amount of miltefosine, such as an oral or intravenous formulation, and optionally administration of one or more secondary agents. The methods may alleviate or abrogate the viral infection and may further lessen the effects of the cytokine and/or bradykinin storms that occur in certain subjects.
Abstract: Methods of determining whether specific drugs or patients carry an increased risk of causing or developing, respectively, long QT syndrome or Torsades de Pointes and methods of treating such patients.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
November 7, 2023
Assignee:
TABULA RASA HEALTHCARE, INC.
Inventors:
Jacques Turgeon, Lauren E. Steffen, Gabriel Badea, Veronique Michaud
Abstract: Vaginal lubricants that have salts which are biomatched to salts that are naturally present in the vagina facilitate intercourse without toxic effects. Topical substances that have a low buffering capacity to promote fertility by providing lubricity while minimizing disturbance to the natural pH levels present during intercourse. A low buffering capacity reduces the extent to which a product interferes with natural pH and buffering capacity of fluids that are present during intercourse.
Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Type:
Grant
Filed:
March 16, 2023
Date of Patent:
November 7, 2023
Assignee:
SPRINGWORKS THERAPEUTICS, INC.
Inventors:
Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
Type:
Grant
Filed:
April 23, 2021
Date of Patent:
November 7, 2023
Assignee:
HARM REDUCTION THERAPEUTICS, INC.
Inventors:
John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
Abstract: A method of extracting a C. Yanhusuo plant comprising the steps of harvesting and drying the plant; extracting the alkaloids from the plant in a solvent; filtering the solvent-C. Yanhusuo plant mixture to remove the solvent and extracted alkaloids from a spent plant matter; drying the spent plant matter; purifying and separating the extracted alkaloids from the solvent; and mixing the purified alkaloids back into the dried spent plant matter. Also, products of the method include vaporizing liquids, medicinal compositions, kief compositions, rolling papers, and filters for tobacco and vaporizing equipment comprising the mixture of the purified alkaloids and the dried spent plant matter produced according to the method. Further, a C. Yanhusuo plant having a total alkaloid content of about 3%, of which 97% of the total alkaloid content is bulbocapnine and tetrahydropalmatine (THP).
Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
Type:
Grant
Filed:
October 25, 2022
Date of Patent:
October 24, 2023
Assignees:
YALE UNIVERSITY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora